What prices were involved in the RVMD CFO’s option exercise and share sale?

The stock option was exercised at an exercise price of $42.45 per share , and the 10,000 common shares sold in the same report were sold at $98 per share .

Revolution Medicines (RVMD) CFO exercises options and sells 10,000 shares

Q: Was the RVMD CFO’s stock sale part of a 10b5-1 trading plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted by Jack Anders on December 16, 2024 .

Q: What is Jack Anders’ role at Revolution Medicines?

Jack Anders is identified in the filing as an officer of Revolution Medicines, serving as the company’s Chief Financial Officer .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Revolution Medicines Chief Financial Officer Jack Anders reported an exercise and sale of company stock. On January 7, 2026, he exercised a stock option for 10,000 shares of common stock at an exercise price of $42.45 per share, then sold 10,000 shares of common stock at a price of $98 per share. The filing states this activity was carried out under a Rule 10b5-1 trading plan adopted on December 16, 2024, indicating it was pre‑scheduled. Following these transactions, Anders beneficially owned 108,065 shares of common stock, which includes 42,338 restricted stock units, and held 15,900 stock options directly.

Insider Trade Summary

Exercise and Sale: 10,000 shares ($556K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Anders Jack

Role Chief Financial Officer

Sold 10,000 shs ($980K)

Approx. gross sale proceeds $980K

Approx. exercise cost $425K

Approx. pre-tax spread $556K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$42.45	$425K
Sale	Common Stock	10,000	$98.00	$980K

Holdings After Transaction: Stock Option (Right to Buy) — 15,900 shares (Direct); Common Stock — 108,065 shares (Direct)

Footnotes (2)

F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
F2. Includes 42,338 restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/09/2026 - 04:20 PM

FAQ

What insider transaction did RVMD's CFO report on January 7, 2026?

On January 7, 2026, Revolution Medicines Chief Financial Officer Jack Anders exercised a stock option for 10,000 shares of common stock at $42.45 per share and sold 10,000 shares of common stock at $98 per share.

Was the RVMD CFO’s stock sale part of a 10b5-1 trading plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted by Jack Anders on December 16, 2024.

How many Revolution Medicines shares does the CFO own after this Form 4?

After the reported transactions, Jack Anders beneficially owned 108,065 shares of common stock, which the filing notes include 42,338 restricted stock units.

What stock options does the RVMD CFO hold after the transaction?

Following the option exercise on January 7, 2026, Jack Anders held 15,900 stock options directly, in addition to his common stock holdings.

What is Jack Anders’ role at Revolution Medicines?

Jack Anders is identified in the filing as an officer of Revolution Medicines, serving as the company’s Chief Financial Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		M⁽¹⁾		10,000	A	$42.45	118,065⁽²⁾	D
Common Stock	01/07/2026		S⁽¹⁾		10,000	D	$98	108,065⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$42.45	01/07/2026		M⁽¹⁾			10,000	03/04/2025	03/03/2031	Common Stock	10,000	$0	15,900	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.

2. Includes 42,338 restricted stock units.

	/s/ Jack Anders	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR